《復牌公告》再鼎醫藥(09688.HK)發售美國預託股份 淨籌7.15億美元
再鼎醫藥(09688.HK)公布,公司向於美國發售477.6萬股美國預託股份(每股美國預託股份代表1股公司普通股)的定價為每股美國預託股份150美元,而500萬股普通股的定價為每股普通股1,164.2港元,涉及發行股份數目佔擴大後美國預託股份約7.36%。
公司預計,是次發售所得款項淨額為7.15億美元,主要用作增加業務及企業發展活動、推進多種候選藥物的臨床開發、拓展公司的商業化工作,及用於營運資金及其他一般企業用途。
該公司今日(21日)復牌。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.